US FDA Launches Global Reliance Disclosure Programme to Support Faster Access to Medicines
US FDA launches Global Reliance Disclosure Programme to enable applicants to share minimally redacted drug and biologic approval packages with foreign regulatory authorities, potentially reducing review timelines and supporting wider patient access to medicines.
Scientific And Regulatory Assessments | 19/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy